THERAVANCE INC (THRX) is a publicly traded company in the Unknown sector. Across all available filings, 45 corporate insiders have executed 854 transactions totaling $471.9M, demonstrating a bullish sentiment with $344.6M in net insider flow. The most recent transaction on Feb 14, 2024 involved a transaction of 8,150.23 shares valued at $0.
No significant insider buying has been recorded for THRX in the recent period.
No significant insider selling has been recorded for THRX in the recent period.
Based on recent SEC filings, insider sentiment for THRX is bullish with an Insider Alignment Score of 87/100 and a net flow of $344.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at THERAVANCE INC (THRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 45 insiders are actively trading THRX stock, having executed 854 transactions in the past 90 days. The most active insider is Plc Glaxosmithkline (Executive), who has made 21 transactions totaling $366.4M.
Get notified when executives and directors at THRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 14, 2024 | D. Dahms Bradford | Executive | Tender | 8,150.23 | $N/A | $0 | |
| Feb 14, 2024 | D. Dukes Iain | Executive | Tender | 388,324 | $N/A | $0 | |
| Feb 14, 2024 | L. Gordon Carl | Executive | Tender | 650,600 | $N/A | $0 | |
| Feb 14, 2024 | L. Gordon Carl | Executive | Tender | 17,063,000 | $N/A | $0 | |
| Feb 14, 2024 | J. Hayden Donald Jr | Executive | Tender | 10,000 | $N/A | $0 | |
| Feb 14, 2024 | Llc Orbimed Advisors | Executive | Tender | 17,063,000 | $N/A | $0 | |
| Feb 14, 2024 | Llc Orbimed Advisors | Executive | Tender | 650,600 | $N/A | $0 | |
| Nov 6, 2023 | Shakespeare William | Executive | Option Exercise | 251,084 | $0.32 | $80.3K | |
| Jul 17, 2023 | Opportunity Management V, Llc Foresite Capital | Executive | Purchase | 523,450 | $2.97 | $1.6M | Large |
| Jul 17, 2023 | Opportunity Management V, Llc Foresite Capital | Executive | Purchase | 176,550 | $2.97 | $524.4K | Large |
| Jul 17, 2023 | Llc Orbimed Advisors | Executive | Purchase | 151,450 | $3.05 | $461.9K | |
| Jul 17, 2023 | Llc Orbimed Advisors | Executive | Purchase | 328,482 | $3.05 | $1.0M | Large |
| Jul 17, 2023 | L. Gordon Carl | Executive | Purchase | 328,482 | $3.05 | $1.0M | Large |
| Jul 17, 2023 | L. Gordon Carl | Executive | Purchase | 151,450 | $3.05 | $461.9K | |
| Dec 30, 2022 | J. Hayden Donald Jr | Executive | Purchase | 9,900 | $5.00 | $49.5K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 107 | $408.3M | 79.3% |
Sale(S) | 303 | $63.7M | 12.4% |
Exercise(M) | 79 | $27.8M | 5.4% |
Payment(F) | 122 | $14.9M | 2.9% |
Disposition(D) | 2 | $40.3K | 0.0% |
Tender(U) | 7 | $0 | 0.0% |
Conversion(C) | 9 | $0 | 0.0% |
Award(A) | 177 | $0 | 0.0% |
Gift(G) | 23 | $0 | 0.0% |
Other(J) | 24 | $0 | 0.0% |
Will Acquisition(W) | 1 | $0 | 0.0% |
Insiders at THERAVANCE INC are accumulating shares at an accelerated pace. With 45 insiders making 854 transactions totaling $408.3M in purchases versus $63.7M in sales, the net buying activity of $344.6M signals strong executive confidence. Plc Glaxosmithkline (Executive) leads the buying activity with $366.4M in transactions across all time.